Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | USP10 | Q14694 | 1/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | USP13 | Q92995 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27893661 | 0.83 | GRIN2D (0.49) | KDM4E | |
| SCHEMBL12466282 | 0.83 | KDM5A (0.50) | HPGDCCNT1CDK9NTRK1NTRK3 | |
| SCHEMBL1391528 | 0.75 | KCNH3 (0.49) | KDM4ELMNAKCNH3 | |
| SCHEMBL5176205 | 0.75 | ARG1 (0.46) | KDM4E | |
| SCHEMBL6078208 | 0.75 | MEN1 (0.57) | P4HTMLMNAKCNH3PPARASTING1 | |
| SCHEMBL17233219 | 0.74 | SMARCA2 (0.45) | — | |
| SCHEMBL6756755 | 0.74 | GHSR (0.46) | — | |
| SCHEMBL6692354 | 0.73 | PPARA (0.54) | HPGDKCNH3PPARASTING1 | |
| SCHEMBL14101817 | 0.73 | RECQL (0.48) | — | |
| SCHEMBL19062199 | 0.73 | SMARCA2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675830-A4 | HETEROCYCLIC AMIDES AND SULFONAMIDES | SCIOS INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20060199821-A1 | Heterocyclic amides and sulfonamides | SCIOS, INC. (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1675830-A2 | HETEROCYCLIC AMIDES AND SULFONAMIDES | SCIOS INC. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005033072-A2 | HETEROCYCLIC AMIDES AND SULFONAMIDES | SCIOS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199821-A1 | Heterocyclic amides and sulfonamides | MAP4K2, MAP3K8, MAP3K2 | KDM4E 1464/4885ALDH1A1 2599/4885HPGD 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.